+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Europe RNA Based Therapeutic Market By Type, By Application, By End User, By Country, Opportunity Analysis and Industry Forecast, 2021-2027

  • PDF Icon

    Report

  • 83 Pages
  • January 2022
  • Region: Europe
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5552984
The Europe RNA Based Therapeutic Market is expected to witness market growth of 14.9% CAGR during the forecast period (2021-2027).

RNA-based therapies have been investigated as a possible treatment option for difficult-to-treat disorders. The therapies are being developed using promising technologies including RNA interference technology (RNAi) and antisense technology. In addition, with the incorporation of RNAi techniques in personalized medicine and molecular diagnostics, cancer detection and therapy are currently undergoing a change. Small interfering RNAs (siRNA) or microRNAs (miRNA) can also be used for diagnostic purposes.

Because of the growing demand for RNA therapies to tackle unmet medical needs, non-profit organizations have pooled their financial resources to accelerate the development of RNA therapeutics. In addition, the growing desire for personalized medicine to improve clinical outcomes and pharmaceutical safety has supported the expansion of the RNA vaccines market. In the treatment of cancer, personalized therapy is crucial (large patient population).

Because of increased RNA research activities in collaboration with government organizations, the UK RNA-based Therapeutics and Vaccines market holds a significant position in Europe. Additionally, the number of manufacturers of RNA is increasing in Germany, owing to which, Germany holds the second largest share in Europe RNA based therapeutics and vaccines. Moreover, the increasing geriatric population across the region is another reason for the development of RNA-based therapeutics in Europe. According to the data shared by Eurostat, in 2020, more than a fifth of the EU population (20.6 percent) will be 65 or older. Between 2020 and 2100, the proportion of people aged 80 and up in the EU population is expected to increase by two and a half times, from 5.9% to 14.6 percent.

The Germany market dominated the Europe RNA Based Therapeutic Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $693.9 million by 2027. The UK market is poised to grow at a CAGR of 14% during (2021 - 2027). Additionally, The France market is expected to exhibit a CAGR of 15.7% during (2021 - 2027).

Based on Type, the market is segmented into RNA Antisense and RNA Interference (RNAi). Based on Application, the market is segmented into Genetic disorders and Auto immune disorders. Based on End User, the market is segmented into Research Institutes and Hospitals & Clinics. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Inc., Benitec Biopharma, Inc., Alnylam Pharmaceuticals, Inc., Sanofi S.A. (Sanofi Genzyme), Biogen, Inc., Gradalis, Inc., Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., and Silence Therapeutics Plc.

Scope of the Study


Market Segments Covered in the Report:


By Type

  • RNA Antisense
  • RNA Interference (RNAi)

By Application

  • Genetic disorders
  • Auto immune disorders

By End User

  • Research Institutes
  • Hospitals & Clinics

By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Key Market Players


List of Companies Profiled in the Report:

  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • Benitec Biopharma, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Sanofi S.A. (Sanofi Genzyme)
  • Biogen, Inc.
  • Gradalis, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.
  • Silence Therapeutics Plc

Unique Offerings from the Publisher

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe RNA Based Therapeutic Market, by Type
1.4.2 Europe RNA Based Therapeutic Market, by Application
1.4.3 Europe RNA Based Therapeutic Market, by End User
1.4.4 Europe RNA Based Therapeutic Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr - 2022, Jan) Leading Players
Chapter 4. Europe RNA Based Therapeutic Market by Type
4.1 Europe RNA Antisense Market by Country
4.2 Europe RNA Interference (RNAi) Market by Country
Chapter 5. Europe RNA Based Therapeutic Market by Application
5.1 Europe Genetic disorders Market by Country
5.2 Europe Auto immune disorders Market by Country
Chapter 6. Europe RNA Based Therapeutic Market by End User
6.1 Europe Research Institutes Market by Country
6.2 Europe Hospitals & Clinics Market by Country
Chapter 7. Europe RNA Based Therapeutic Market by Country
7.1 Germany RNA Based Therapeutic Market
7.1.1 Germany RNA Based Therapeutic Market by Type
7.1.2 Germany RNA Based Therapeutic Market by Application
7.1.3 Germany RNA Based Therapeutic Market by End User
7.2 UK RNA Based Therapeutic Market
7.2.1 UK RNA Based Therapeutic Market by Type
7.2.2 UK RNA Based Therapeutic Market by Application
7.2.3 UK RNA Based Therapeutic Market by End User
7.3 France RNA Based Therapeutic Market
7.3.1 France RNA Based Therapeutic Market by Type
7.3.2 France RNA Based Therapeutic Market by Application
7.3.3 France RNA Based Therapeutic Market by End User
7.4 Russia RNA Based Therapeutic Market
7.4.1 Russia RNA Based Therapeutic Market by Type
7.4.2 Russia RNA Based Therapeutic Market by Application
7.4.3 Russia RNA Based Therapeutic Market by End User
7.5 Spain RNA Based Therapeutic Market
7.5.1 Spain RNA Based Therapeutic Market by Type
7.5.2 Spain RNA Based Therapeutic Market by Application
7.5.3 Spain RNA Based Therapeutic Market by End User
7.6 Italy RNA Based Therapeutic Market
7.6.1 Italy RNA Based Therapeutic Market by Type
7.6.2 Italy RNA Based Therapeutic Market by Application
7.6.3 Italy RNA Based Therapeutic Market by End User
7.7 Rest of Europe RNA Based Therapeutic Market
7.7.1 Rest of Europe RNA Based Therapeutic Market by Type
7.7.2 Rest of Europe RNA Based Therapeutic Market by Application
7.7.3 Rest of Europe RNA Based Therapeutic Market by End User
Chapter 8. Company Profiles
8.1 Arbutus Biopharma Corporation
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.1.4 Recent strategies and developments
8.1.4.1 Partnerships, Collaborations, and Agreements
8.1.4.2 Acquisitions, Mergers and Joint Ventures:
8.2 Arrowhead Pharmaceuticals, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments
8.2.4.1 Partnerships, Collaborations, and Agreements
8.3 Benitec Biopharma, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Research & Development Expenses
8.4 Alnylam Pharmaceuticals, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Research & Development Expense
8.4.4 Recent strategies and developments
8.4.4.1 Partnerships, Collaborations, and Agreements
8.4.4.2 Approvals and Trials
8.5 Sanofi S.A. (Sanofi Genzyme)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments
8.5.5.1 Partnerships, Collaborations, and Agreements
8.5.5.2 Acquisition and Mergers:
8.6 Biogen, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments
8.6.5.1 Partnerships, Collaborations, and Agreements
8.7 Gradalis, Inc.
8.7.1 Company Overview
8.8 Ionis Pharmaceuticals, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments
8.8.5.1 Partnerships, Collaborations, and Agreements
8.9 Sarepta Therapeutics, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Research & Development Expenses
8.9.4 Recent strategies and developments
8.9.4.1 Partnerships, Collaborations, and Agreements
8.10. Silence Therapeutics Plc
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments
8.10.4.1 Partnerships, Collaborations, and Agreements

Companies Mentioned

  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • Benitec Biopharma, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Sanofi S.A. (Sanofi Genzyme)
  • Biogen, Inc.
  • Gradalis, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.
  • Silence Therapeutics Plc

Methodology

Loading
LOADING...